IDEXX Laboratories, Inc. (IDXX)
Nasdaq · Healthcare · Diagnostics & Research
$527.07+1.67%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $41.5B
- P/E (trailing)
- 37.0
- Forward P/E
- 31.5
- 52-week range
- $500.61 – $769.98
- 52-week change
- −17.42%
- EPS (trailing)
- $14.23
- Analyst rating
- 2.2 Buy
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $4.3B (+10.42%)
- Net income
- $1.1B
- Operating margin
- 31.6%
- Diluted EPS
- $13.08
- Free cash flow
- $1.1B
From the company’s annual report on SEC EDGAR.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E.
Headquarters: Westbrook, United States · 11,000 employees · idexx.com